多嚢胞性卵巣症候群治療の世界市場レポート 2025年

多嚢胞性卵巣症候群治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で68億1,000万米ドルに成長します。予測期間の成長は、個別化医療、遠隔医療と遠隔モニタリング、研究開発、普及率の上昇、支持的な規制環境に起因すると考えられます。予測期間の主な動向には、全人的アプローチ、患者中心のケア、デジタルヘルスソリューション、集学的ケア、患者教育などがあります。

多嚢胞性卵巣症候群（PCOS）治療市場の成長を促す主な要因は、遺伝性疾患とホルモン疾患の世界の増加です。PCOSは閉経前女性に影響を及ぼす一般的なホルモン疾患で、生殖、内分泌、代謝の異常を特徴とします。PCOSの世界の有病率は2.2％から26％で、地域差があります。例えば、中国では2％から7.5％、スリランカでは6.3％、南インドでは9.13％、マハラシュトラ州では22.5％と報告されています。世界の遺伝的・ホルモン的疾患の罹患率の増加は、PCOS治療市場の成長に大きく寄与すると予想されます。

ライフスタイルと食生活の変化の急増は、多嚢胞性卵巣症候群治療市場の成長を促進すると予想されます。ライフスタイルや食生活の変化は、日常生活や食習慣の変更を含み、PCOSの管理や治療に大きな影響を与える可能性があります。これらの変化は、PCOS患者の症状を緩和し、全体的な幸福感を高めるための主要な、あるいは補完的なアプローチとして採用されることが多いです。例えば、2022年10月のマッキンゼー・アンド・カンパニーの記事では、健康的な食事の重要性が強調されており、様々な国の調査回答者の少なくとも70％が健康的でありたいという願望を表明しています。健康的な食事は、あらゆる年齢層の消費者の約半数にとって優先事項です。従って、ライフスタイルや食生活の変化が多嚢胞性卵巣症候群治療市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界多嚢胞性卵巣症候群治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の多嚢胞性卵巣症候群治療市場：成長率分析
• 世界の多嚢胞性卵巣症候群治療市場の実績：規模と成長, 2019-2024
• 世界の多嚢胞性卵巣症候群治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界多嚢胞性卵巣症候群治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多嚢胞性卵巣症候群治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口避妊薬
• オルニチン脱炭酸酵素阻害剤
• インスリン抵抗性改善薬
• 抗うつ薬
• 利尿剤
• アロマターゼ阻害剤
• 世界の多嚢胞性卵巣症候群治療市場手術の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 卵巣楔状切除術
• 腹腔鏡下卵巣穿孔術
• 世界の多嚢胞性卵巣症候群治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外来手術センター
• 診断センター
• 婦人科センター
• フェミニスト健康センター
• 世界の多嚢胞性卵巣症候群治療市場経口避妊薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 複合経口避妊薬（COC）
• プロゲスチンのみのピル
• 世界の多嚢胞性卵巣症候群治療市場オルニチン脱炭酸酵素阻害剤の標的別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 卵巣アンドロゲン産生を標的とした薬剤
• ポリアミン合成を標的とする阻害剤
• 世界の多嚢胞性卵巣症候群治療市場インスリン抵抗性改善薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトホルミン
• チアゾリジンジオン（TZD）
• 世界の多嚢胞性卵巣症候群治療市場抗うつ薬の作用機序によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的セロトニン再取り込み阻害薬（SSRI）
• セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
• 世界の多嚢胞性卵巣症候群治療市場利尿薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• スピロノラクトン
• フロセミド
• 世界の多嚢胞性卵巣症候群治療市場アロマターゼ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レトロゾール
• アナストロゾール

第7章 地域別・国別分析

• 世界の多嚢胞性卵巣症候群治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多嚢胞性卵巣症候群治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多嚢胞性卵巣症候群治療市場：競合情勢
• 多嚢胞性卵巣症候群治療市場：企業プロファイル
  • Bristol-Myer Squibb Co Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• Teva Pharmaceutical Industries Limited
• Abbott Laboratories
• Addex Therapeutics Ltd.
• BIOCAD
• Allergan plc.
• Johnson and Johnson
• Ferring Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Limited
• Organon & Co
• Forendo Pharma Ltd.
• GlaxoSmithKline plc
• AbbVie Inc.
• Eli Lilly and Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多嚢胞性卵巣症候群治療市場2029：新たな機会を提供する国
• 多嚢胞性卵巣症候群治療市場2029：新たな機会を提供するセグメント
• 多嚢胞性卵巣症候群治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Polycystic ovarian syndrome (PCOS) is a condition characterized by hormonal imbalances in females, resulting in elevated levels of male hormones, which in turn can lead to irregular menstrual cycles and increased difficulty in achieving pregnancy.

The primary categories of drugs used in the treatment of polycystic ovarian syndrome include oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, and aromatase inhibitors. Oral contraceptives are hormone-based medications taken orally to prevent pregnancy. They work by inhibiting ovulation and preventing sperm from reaching the cervix. Various surgical procedures, such as ovarian wedge resection and laparoscopic ovarian drilling, are performed in medical facilities, including hospitals, clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, and feminist health centers.

The polycystic ovarian syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides polycystic ovarian syndrome treatment market statistics, including polycystic ovarian syndrome treatment industry global market size, regional shares, competitors with a polycystic ovarian syndrome treatment market share, detailed polycystic ovarian syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the polycystic ovarian syndrome treatment industry. This polycystic ovarian syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The polycystic ovarian syndrome treatment market size has grown strongly in recent years. It will grow from $4.78 billion in 2024 to $5.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increased awareness, advances in medical technology, lifestyle changes, pharmaceutical innovations, government initiatives.

The polycystic ovarian syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to personalized medicine, telemedicine and remote monitoring, research and development, rising prevalence, supportive regulatory environment. Major trends in the forecast period include holistic approach, patient-centered care, digital health solutions, multidisciplinary care, patient education.

The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS, a common hormonal disorder affecting premenopausal women, is characterized by reproductive, endocrine, and metabolic abnormalities. The global prevalence of PCOS ranges from 2.2% to 26%, with regional variations. For instance, it is reported at 2% to 7.5% in China, 6.3% in Sri Lanka, 9.13% in South India, and 22.5% in Maharashtra. The increasing incidence of genetic and hormonal disorders worldwide is expected to contribute significantly to the growth of the PCOS treatment market.

The surge in lifestyle and dietary changes is anticipated to propel the growth of the polycystic ovarian syndrome treatment market. Lifestyle and dietary changes involve modifying daily routines and eating habits, which can significantly impact the management and treatment of PCOS. These changes are often employed as primary or complementary approaches to alleviate symptoms and enhance the overall well-being of individuals with PCOS. For example, a McKinsey & Company article from October 2022 highlights the importance of healthy eating, with at least 70% of survey respondents in various countries expressing a desire to be healthy. Healthy eating is a priority for around half of consumers across all age groups. Hence, the increase in lifestyle and dietary changes is fostering the growth of the polycystic ovarian syndrome treatment market.

Major companies in the polycystic ovarian syndrome (PCOS) treatment market are focusing on strategic partnerships to develop comprehensive diagnostic test kits aimed at improving early detection and enabling timely intervention. This approach enhances treatment outcomes and meets the increasing demand for accurate and accessible diagnostic tools. Diagnostic test kits are designed to identify diseases or conditions by analyzing bodily samples such as blood or urine. For example, in October 2022, Veera Health, an India-based wellness and fitness service provider, collaborated with Tata 1mg, an India-based healthcare company, to introduce a comprehensive test for diagnosing PCOS. The diagnostic test kit plays a crucial role in detecting the condition early, which allows for personalized and targeted treatment plans. By utilizing a comprehensive approach, these kits provide insights into hormonal levels, metabolic markers, and other relevant factors, ensuring individuals receive accurate diagnoses for effective PCOS management.

Major companies operating in the polycystic ovarian syndrome treatment market are introducing innovative programs like the PCOS Drug Program to enhance their market presence. The PCOS Drug Program is a treatment plan that combines lifestyle modifications and medications to manage PCOS symptoms. For example, in April 2023, Celmatix Inc., a US-based biotech company, launched the PCOS Drug Program with the primary goal of improving ovarian function by addressing the root cause of PCOS symptoms. The program's latest medication initiative focuses on developing the first-ever oral FSH receptor.

Major companies operating in the polycystic ovarian syndrome treatment market include Bristol-Myer Squibb Co, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi SA, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Addex Therapeutics Ltd., BIOCAD, Allergan plc., Johnson and Johnson, Ferring Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Organon & Co, Forendo Pharma Ltd., GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Mylan NV, Lupin Pharmaceuticals Inc., HRA Pharma SAS, CooperSurgical Inc., TherapeuticsMD Inc., Agile Therapeutics Inc., OvaScience Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Limited

North America was the largest region in the polycystic ovarian syndrome treatment market in 2024. Western Europe was the second largest region in the polycystic ovarian syndrome treatment market. The regions covered in the polycystic ovarian syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the polycystic ovarian syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The polycystic ovarian syndrome treatment market includes revenue earned by first line drugs for treating hirustism, first line drugs for ovulation, and insulin sensitizing drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Polycystic Ovarian Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on polycystic ovarian syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for polycystic ovarian syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The polycystic ovarian syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Oral Contraceptives; Ornithine Decarboxylase Inhibitors; Insulin-Sensitizing Agents; Anti-Depressants; Diuretics; Aromatase Inhibitors
• 2) By Surgery Type: Ovarian Wedge Resection; Laparoscopic Ovarian Drilling
• 3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Gynecology Centers, Feminist Health Centers
• Subsegments:
• 1) By Oral Contraceptives: Combined Oral Contraceptives (COCs); Progestin-Only Pills
• 2) By Ornithine Decarboxylase Inhibitors: Drugs Targeting Ovarian Androgen Production; Inhibitors Targeting Polyamine Synthesis
• 3) By Insulin-Sensitizing Agents: Metformin; Thiazolidinediones (TZDs)
• 4) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• 5) By Diuretics: Spironolactone; Furosemide
• 6) By Aromatase Inhibitors: Letrozole; Anastrozole
• Companies Mentioned: Bristol-Myer Squibb Co; Bayer AG; Pfizer Inc.; Merck KGaA; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Polycystic Ovarian Syndrome Treatment Market Characteristics

3. Polycystic Ovarian Syndrome Treatment Market Trends And Strategies

4. Polycystic Ovarian Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Polycystic Ovarian Syndrome Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Polycystic Ovarian Syndrome Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Polycystic Ovarian Syndrome Treatment Market Growth Rate Analysis
• 5.4. Global Polycystic Ovarian Syndrome Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Polycystic Ovarian Syndrome Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Polycystic Ovarian Syndrome Treatment Total Addressable Market (TAM)

6. Polycystic Ovarian Syndrome Treatment Market Segmentation

• 6.1. Global Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Contraceptives
• Ornithine Decarboxylase Inhibitors
• Insulin-Sensitizing Agents
• Anti-Depressants
• Diuretics
• Aromatase Inhibitors
• 6.2. Global Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ovarian Wedge Resection
• Laparoscopic Ovarian Drilling
• 6.3. Global Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Diagnostic Centers
• Gynecology Centers
• Feminist Health Centers
• 6.4. Global Polycystic Ovarian Syndrome Treatment Market, Sub-Segmentation Of Oral Contraceptives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combined Oral Contraceptives (COCs)
• Progestin-Only Pills
• 6.5. Global Polycystic Ovarian Syndrome Treatment Market, Sub-Segmentation Of Ornithine Decarboxylase Inhibitors, By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs Targeting Ovarian Androgen Production
• Inhibitors Targeting Polyamine Synthesis
• 6.6. Global Polycystic Ovarian Syndrome Treatment Market, Sub-Segmentation Of Insulin-Sensitizing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metformin
• Thiazolidinediones (TZDs)
• 6.7. Global Polycystic Ovarian Syndrome Treatment Market, Sub-Segmentation Of Anti-Depressants, By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• 6.8. Global Polycystic Ovarian Syndrome Treatment Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spironolactone
• Furosemide
• 6.9. Global Polycystic Ovarian Syndrome Treatment Market, Sub-Segmentation Of Aromatase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Letrozole
• Anastrozole

7. Polycystic Ovarian Syndrome Treatment Market Regional And Country Analysis

• 7.1. Global Polycystic Ovarian Syndrome Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Polycystic Ovarian Syndrome Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market

• 8.1. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Polycystic Ovarian Syndrome Treatment Market

• 9.1. China Polycystic Ovarian Syndrome Treatment Market Overview
• 9.2. China Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Polycystic Ovarian Syndrome Treatment Market

• 10.1. India Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Polycystic Ovarian Syndrome Treatment Market

• 11.1. Japan Polycystic Ovarian Syndrome Treatment Market Overview
• 11.2. Japan Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Polycystic Ovarian Syndrome Treatment Market

• 12.1. Australia Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Polycystic Ovarian Syndrome Treatment Market

• 13.1. Indonesia Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Polycystic Ovarian Syndrome Treatment Market

• 14.1. South Korea Polycystic Ovarian Syndrome Treatment Market Overview
• 14.2. South Korea Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Polycystic Ovarian Syndrome Treatment Market

• 15.1. Western Europe Polycystic Ovarian Syndrome Treatment Market Overview
• 15.2. Western Europe Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Polycystic Ovarian Syndrome Treatment Market

• 16.1. UK Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Polycystic Ovarian Syndrome Treatment Market

• 17.1. Germany Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Polycystic Ovarian Syndrome Treatment Market

• 18.1. France Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Polycystic Ovarian Syndrome Treatment Market

• 19.1. Italy Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Polycystic Ovarian Syndrome Treatment Market

• 20.1. Spain Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Polycystic Ovarian Syndrome Treatment Market

• 21.1. Eastern Europe Polycystic Ovarian Syndrome Treatment Market Overview
• 21.2. Eastern Europe Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Polycystic Ovarian Syndrome Treatment Market

• 22.1. Russia Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Polycystic Ovarian Syndrome Treatment Market

• 23.1. North America Polycystic Ovarian Syndrome Treatment Market Overview
• 23.2. North America Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Polycystic Ovarian Syndrome Treatment Market

• 24.1. USA Polycystic Ovarian Syndrome Treatment Market Overview
• 24.2. USA Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Polycystic Ovarian Syndrome Treatment Market

• 25.1. Canada Polycystic Ovarian Syndrome Treatment Market Overview
• 25.2. Canada Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Polycystic Ovarian Syndrome Treatment Market

• 26.1. South America Polycystic Ovarian Syndrome Treatment Market Overview
• 26.2. South America Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Polycystic Ovarian Syndrome Treatment Market

• 27.1. Brazil Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Polycystic Ovarian Syndrome Treatment Market

• 28.1. Middle East Polycystic Ovarian Syndrome Treatment Market Overview
• 28.2. Middle East Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Polycystic Ovarian Syndrome Treatment Market

• 29.1. Africa Polycystic Ovarian Syndrome Treatment Market Overview
• 29.2. Africa Polycystic Ovarian Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Polycystic Ovarian Syndrome Treatment Market, Segmentation By Surgery Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Polycystic Ovarian Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Polycystic Ovarian Syndrome Treatment Market Competitive Landscape And Company Profiles

• 30.1. Polycystic Ovarian Syndrome Treatment Market Competitive Landscape
• 30.2. Polycystic Ovarian Syndrome Treatment Market Company Profiles
  • 30.2.1. Bristol-Myer Squibb Co Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Polycystic Ovarian Syndrome Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. Teva Pharmaceutical Industries Limited
• 31.4. Abbott Laboratories
• 31.5. Addex Therapeutics Ltd.
• 31.6. BIOCAD
• 31.7. Allergan plc.
• 31.8. Johnson and Johnson
• 31.9. Ferring Pharmaceuticals Inc.
• 31.10. Takeda Pharmaceutical Company Limited
• 31.11. Organon & Co
• 31.12. Forendo Pharma Ltd.
• 31.13. GlaxoSmithKline plc
• 31.14. AbbVie Inc.
• 31.15. Eli Lilly and Company

32. Global Polycystic Ovarian Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Polycystic Ovarian Syndrome Treatment Market

34. Recent Developments In The Polycystic Ovarian Syndrome Treatment Market

35. Polycystic Ovarian Syndrome Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Polycystic Ovarian Syndrome Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Polycystic Ovarian Syndrome Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Polycystic Ovarian Syndrome Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer